Loading...

Opthea Limited

OPTNASDAQ
Healthcare
Biotechnology
$3.41
$0.05(1.49%)

Opthea Limited (OPT) Stock Overview

Explore Opthea Limited’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 64.3/100

Key Financials

Market Cap4.2B
P/E Ratio-1.64
EPS (TTM)$-2.25
ROE2.60%
Fundamental Analysis

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 Months$4.38
1 Year Target$4.08

OPT Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Opthea Limited (OPT) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $4.08.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -1.64 and a market capitalization of 4.2B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Revenue Growth
-22.65%
22.65%
Profit Growth
$-0.26
3.95%
EPS Growth
$-0.26
22.22%
Operating Margin
-328804.39%
14.14%
ROE
259.61%
3.95%
Dividend Yield
0.00%

Analyst Recommendations

Strong Buy
0
Buy
0
Hold
1
Sell
1
Strong Sell
0

Price Targets

Low$2.00
Average$2.00
High$2.00

Company Profile

Opthea Limited, a clinical stage biopharmaceutical company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead asset is OPT 302, a soluble form of VEGFR 3 in clinical development as a novel therapy for wet neovascular age related macular degeneration and diabetic macular edema DME, as well as a first in class VEGF C/D inhibitors for treatment with VEGF A inhibitors for the treatment of wet neovascular AMD and other retinal diseases. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.

CEO

Frederic Guerard

Employees

33

Headquarters

650 Chapel Street, South Yarra, VIC

Founded

2020

Frequently Asked Questions

;